Magellan: Upgrade Ali Health (00241.HK) rating to "outperform the market" with a target price increased to 6.78 Hong Kong dollars.

According to the AI Financial APP, Macquarie released a research report stating that it has upgraded the rating of Alibaba Health (00241.HK) from "underperform market" to "outperform market", and raised the adjusted net profit forecast for 2026 and 2027 financial years by 6% and 20%, reflecting the strengthening of market integration and profit-making ability. The target price has been raised from 3.4 Hong Kong dollars to 6.78 Hong Kong dollars.